Chemotherapy can damage the liver, and it does so more often than many patients realize. The liver processes most drugs that enter the bloodstream, so it sits directly in the path of powerful cancer-killing chemicals. Different chemotherapy agents cause different types of liver injury, ranging from mild, temporary enzyme elevations that resolve on their own to serious conditions that can force a change in treatment. The good news is that oncologists routinely monitor liver function during treatment, and most chemotherapy-related liver problems are manageable when caught early.
Why the Liver Is Vulnerable During Chemotherapy
The liver is the body’s main chemical processing plant. Nearly every drug you take passes through it, gets broken down by specialized enzymes, and is either converted into an active form or neutralized for removal. Chemotherapy drugs are designed to be toxic to rapidly dividing cells, but the liver’s own cells take a hit during that processing. The result is a range of possible injuries depending on which drug is involved and how your liver handles it.
The activity of the enzymes responsible for breaking down chemotherapy drugs varies from person to person. When those enzymes work differently than expected, either too slowly or too quickly, you can end up with higher-than-intended levels of the drug or its toxic byproducts circulating through liver tissue. Inflammation caused by the cancer itself can also alter how these enzymes function, compounding the problem.1PubMed Central. Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity
How Different Drugs Cause Different Types of Liver Damage
Not all chemotherapy liver damage looks the same under a microscope or on a scan. The type of injury depends heavily on which drug is involved.
Oxaliplatin, widely used for colorectal cancer, is known for causing a condition called sinusoidal obstruction syndrome. In this condition, the tiny blood vessels inside the liver become blocked and congested, which can lead to liver swelling, pain, and fluid buildup. In severe cases the damage can mimic the appearance of metastatic cancer on imaging, making diagnosis tricky.2PubMed Central. Oxaliplatin-induced sinusoidal obstruction syndrome mimicking metastatic colon cancer in the liver Sinusoidal obstruction syndrome causes enough morbidity that it sometimes forces doctors to stop chemotherapy entirely.3PubMed. Investigating Genetic Risk to Oxaliplatin-Induced Sinusoidal Obstruction Syndrome in Colorectal Cancer Through Routinely Available Next-Generation Sequencing Data
Irinotecan, another colorectal cancer drug, takes a different path. It tends to cause fatty liver disease and steatohepatitis, a combination of fat accumulation and inflammation in liver cells. This type of injury increases the risk of complications if a patient later needs liver surgery for metastatic disease. Patients with a higher body mass index, diabetes, or a high-fat diet face greater risk of this particular problem.4PubMed Central. Irinotecan-Induced Steatohepatitis: Current Insights
Methotrexate, used for certain leukemias and other cancers, is a well-known liver offender especially at high doses. It typically shows up as elevated liver enzymes on blood tests. Arsenic trioxide, used for a specific type of leukemia called acute promyelocytic leukemia, causes liver damage through a combination of oxidative stress, inflammation, and disruption of the energy-producing structures inside liver cells.5PubMed. Ellagic acid and montelukast mitigate arsenic trioxide-induced hepatotoxicity via modulation of oxidative stress, inflammatory pathways, and mitochondrial apoptosis These are just a few examples. The broader point is that chemotherapy liver injury is not one disease but a family of related problems, each with its own mechanism and risk profile.
Who Is at Higher Risk
Some people walk into chemotherapy with livers that are already under stress, and that background matters a lot. Pre-existing fatty liver disease, whether from alcohol, diet, or metabolic conditions, can reduce the liver’s ability to tolerate the additional chemical load of chemotherapy.6PubMed Central. The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review – Section: 3.2. The Effect of Cancer Treatment on NAFLD If your liver is already inflamed or scarred before treatment begins, it has less reserve to absorb the impact.
Hepatitis B deserves special mention here, because chemotherapy can reawaken a virus that seemed to be gone. People who carry hepatitis B, even those who appear to have cleared the infection based on standard blood tests, can experience viral reactivation when chemotherapy suppresses their immune system.7PubMed Central. Management of hepatitis B reactivation in patients receiving cancer chemotherapy The consequences range from a mild flare to fulminant liver failure and death. Even patients who test negative for the surface antigen but positive for core antibody, suggesting past exposure, can be at risk.8PubMed. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management This is why most oncology guidelines now call for hepatitis B screening before starting chemotherapy, and antiviral prophylaxis for patients who test positive.9PubMed Central. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions
Other risk factors are more straightforward: obesity, diabetes, heavy alcohol use, and advanced age all lower the liver’s threshold for injury. Some of these are modifiable. If you are heading into chemotherapy and carry any of these risk factors, it is worth discussing them with your oncologist so they can plan monitoring accordingly.
Signs and Symptoms to Watch For
Mild chemotherapy-related liver injury often produces no symptoms at all. It shows up only on blood tests, which is one reason routine lab monitoring during treatment is so important. When symptoms do appear, they tend to be vague at first and easy to blame on the chemotherapy itself or on the underlying cancer.
Common early signs include fatigue that seems disproportionate to what you’d expect from treatment, loss of appetite, nausea that persists between chemotherapy cycles, and a dull ache or sense of fullness under the right side of the rib cage. More obvious signs of liver trouble include yellowing of the skin or the whites of the eyes, dark-colored urine, pale stools, and itching. Fluid retention in the abdomen, known as ascites, or swelling in the legs can signal more advanced liver compromise.
The challenge is that many of these symptoms overlap with side effects of chemotherapy that have nothing to do with the liver. Nausea and fatigue are nearly universal during treatment. That overlap means you cannot rely on symptoms alone, which brings us to how doctors actually detect liver damage during chemotherapy.
How Doctors Monitor Liver Function During Treatment
Blood tests are the frontline tool. Before each chemotherapy cycle, most oncology protocols call for checking liver enzymes (ALT, AST, alkaline phosphatase, and GGT) along with bilirubin levels. These markers reflect how well your liver cells are functioning and whether they are being damaged. The National Cancer Institute grades these elevations on a scale from mild (slightly above the upper limit of normal) through moderate, severe, and life-threatening, with each grade representing a larger multiple above normal.10PubMed Central. Hepatotoxicity Secondary to Chemotherapy – Section: National Cancer Institute (NCI) common toxicity criteria for adverse events These grades help oncologists decide whether to continue treatment at the current dose, reduce the dose, delay the next cycle, or stop the drug entirely.
An important nuance is that elevated liver labs during chemotherapy do not automatically mean the drug is to blame. One study of nearly 2,800 chemotherapy-treated cancer patients found that when researchers applied a standard method for identifying drug-induced liver injury, about 3% initially appeared to meet the criteria. But after careful review of medical records, the vast majority of those cases had other explanations, such as the tumor itself affecting the liver or pre-existing conditions. Only about 0.07% were left where chemotherapy was the most likely cause of significant liver injury.11PubMed. Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system That does not mean chemotherapy liver damage is rare overall, since many milder enzyme elevations would not meet that strict injury definition. But it does illustrate how hard it can be to pin down the cause when liver numbers go up during cancer treatment.
Imaging plays a supporting role. CT scans and MRIs performed during treatment can reveal structural changes in the liver, including things like nodularity, capsular retraction, widened fissures between liver lobes, and signs of increased pressure in the portal vein system such as an enlarged spleen or fluid in the abdomen.12Diagnosis and Interventional Radiology. Chemotherapy-associated liver morphological changes in hepatic metastases (CALMCHeM) These findings can sometimes be subtle and are easy to overlook when the primary goal of the scan is to assess tumor response.
Newer tools are also being explored. Liver stiffness measurement, done through a non-invasive ultrasound-based technology, has shown promise for detecting oxaliplatin-related sinusoidal injury earlier than standard blood tests. In one study, patients who went on to develop more significant liver damage had measurably stiffer livers at the three- and six-month marks compared to those who did not.13PubMed Central. Comparison Between Liver Stiffness Measurement by Fibroscan and Splenic Volume Index as NonInvasive Tools for the Early Detection of Oxaliplatin-induced Hepatotoxicity This kind of early detection could eventually help oncologists adjust treatment before serious damage occurs.
What Happens When Liver Damage Is Found
The first and most common response is a dose adjustment. Oncology guidelines include specific dose modification rules tied to the severity of liver enzyme elevations.14PubMed Central. Hepatotoxicity Secondary to Chemotherapy – Section: Doses modification guidelines For mild elevations, your oncologist may simply continue treatment with closer monitoring. Moderate elevations often trigger a dose reduction or a delay until the numbers come back down. Severe elevations can mean stopping the offending drug and switching to an alternative if one is available.
This is where the balance gets difficult. The whole point of chemotherapy is to kill cancer cells, and reducing the dose or stopping treatment comes with its own risks. Oncologists weigh the severity of the liver injury against the aggressiveness of the cancer, the availability of alternative regimens, and the patient’s overall condition. There is no universal formula for this decision. It is case by case.
For sinusoidal obstruction syndrome specifically, a drug called defibrotide is the only approved treatment. It is primarily used in severe cases, particularly after high-dose chemotherapy regimens such as those given before bone marrow transplants.15PubMed. Sinusoidal Obstruction Syndrome in Critically Ill Patients in the Era of Defibrotide: A Retrospective Multicenter Study Case reports have documented rapid improvement when defibrotide is started promptly alongside supportive care such as fluid management and pain control.16PubMed. Early-onset severe sinusoidal obstruction syndrome following adjuvant CAPOX: clinicoradiological diagnosis and favourable outcome after treatment with defibrotide Animal studies suggest defibrotide may work better than some other approaches like low-molecular-weight heparin for this type of injury.17PubMed Central. Defibrotide improved the outcome of monocrotaline induced rat hepatic sinusoidal obstruction syndrome
Beyond prescription treatments, researchers have investigated whether natural compounds could offer some liver protection during chemotherapy. Curcumin, the active compound in turmeric, has shown potential in preclinical studies to reduce chemotherapy-induced liver inflammation, oxidative damage, and fat accumulation. However, the research is still largely in the laboratory and animal stage, and clinical trials in cancer patients using well-absorbed curcumin formulations are needed before anyone should rely on it as a protective strategy.18PubMed. Curcumin as a hepatoprotective agent against chemotherapy-induced liver injury If you are interested in any supplement during chemotherapy, talk to your oncologist first, since some supplements can interfere with how chemotherapy drugs are metabolized.
Recovery After Chemotherapy Liver Damage
The liver is famously resilient. It is one of the few organs capable of significant regeneration, and this ability works in favor of most patients who experience chemotherapy-related liver injury. The majority of liver enzyme elevations during treatment are transient, meaning they rise during active chemotherapy and fall once treatment ends or is paused.
A study of children receiving high-dose methotrexate for acute lymphoblastic leukemia illustrated this pattern clearly. While liver enzyme elevations were common during treatment, at three months after the high-dose cycles, ALT had normalized in about 87% of patients, bilirubin in over 93%, and AST and alkaline phosphatase in 100%.19TAJ: Journal of Teachers Association. Hepatotoxic Effects of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia: Patterns, Recovery, and Clinical Implications This is encouraging, though it is worth noting that children generally have healthier livers and stronger regenerative capacity than adults.
Even more dramatic recoveries are possible. A condition called pseudocirrhosis, where chemotherapy-treated liver metastases shrink and leave behind scarring that makes the liver look cirrhotic on imaging, can sometimes reverse completely. In one reported case, a patient with breast cancer whose liver had atrophied and developed all the hallmarks of cirrhosis, including ascites and portal hypertension, saw her liver regenerate to its normal size over the course of a year after appropriate treatment.20PubMed Central. Complete recovery from pseudocirrhosis caused by chemotherapy for diffuse liver metastases of breast cancer Cases like this are not the norm, but they highlight the liver’s remarkable capacity for repair under the right conditions.
That said, not everyone bounces back fully. Patients who develop severe sinusoidal obstruction syndrome, particularly after high-dose chemotherapy for transplant, can suffer lasting damage. Patients with pre-existing liver disease have less reserve to draw on. And patients who need ongoing chemotherapy may accumulate damage over repeated cycles. Recovery depends on the type and severity of the injury, the patient’s baseline liver health, and whether the offending treatment can be stopped or modified.
Immunotherapy and the Liver
Chemotherapy is not the only cancer treatment that affects the liver. Immune checkpoint inhibitors, which have transformed treatment for melanoma, lung cancer, and several other cancers, carry their own risk of liver damage through a completely different mechanism. Instead of direct chemical toxicity, these drugs work by releasing the brakes on the immune system, and sometimes the immune system attacks the liver as collateral damage. This immune-related hepatitis is distinct from chemotherapy-induced liver injury and requires different management, usually steroids rather than dose reduction.21PubMed Central. Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives
The distinction matters because many modern cancer regimens combine chemotherapy with immunotherapy, which means the liver faces threats from both directions. When liver enzymes go up in a patient on a combined regimen, figuring out which agent is responsible is critical, since the treatment for immune-mediated hepatitis (immunosuppression) is essentially the opposite of what you’d want if the liver is struggling with chemical toxicity. Newer targeted therapies like small molecule inhibitors add yet another set of liver-related challenges that oncologists must track.22PubMed Central. Management of hepatotoxicity of chemotherapy and targeted agents
What Imaging Changes Look Like and Why They Can Be Confusing
If you are receiving chemotherapy for cancer that has spread to the liver, your scans may show changes that are alarming but do not necessarily mean things are getting worse. Newer therapies, including targeted drugs and immunotherapy, can cause tumors to undergo changes that look unusual on CT or MRI: internal necrosis, cyst formation, calcification, and fibrosis at the boundary between tumor and normal liver tissue.23PubMed. ESR Essentials: assessing the radiological response of liver metastases to systemic therapy-practice recommendations by the European Society of Gastrointestinal and Abdominal Radiology A tumor that is actually responding to treatment might not shrink right away. It might change in density, develop a ring of fibrosis, or look temporarily larger before eventually regressing.
The liver itself can also change shape during chemotherapy. Specific segments may atrophy while others enlarge, fissures between lobes may widen, and the liver surface can become nodular.12Diagnosis and Interventional Radiology. Chemotherapy-associated liver morphological changes in hepatic metastases (CALMCHeM) These changes can look a lot like cirrhosis from chronic liver disease, which is where the term pseudocirrhosis comes from. If your radiologist or oncologist mentions structural changes in your liver during treatment, it is worth asking whether the changes are thought to reflect treatment response, treatment toxicity, or something else entirely. The answer is not always obvious, even to specialists, which is why radiology guidelines are evolving to better interpret these treatment-related patterns.
Practical Steps You Can Take
You cannot prevent all chemotherapy-related liver injury, but you can reduce your risk and help catch problems early. Before treatment starts, make sure your oncologist knows your full history: any hepatitis exposure, alcohol use, pre-existing liver conditions, and medications or supplements you are taking. Ask whether hepatitis B screening has been done. If you carry the virus, antiviral prophylaxis can prevent a potentially dangerous reactivation.
During treatment, keep all your scheduled blood work appointments. The routine liver function tests ordered before each cycle are your early warning system. If you notice new symptoms like persistent nausea, right-sided abdominal discomfort, unusual fatigue, or yellowing of the skin or eyes between appointments, contact your care team rather than waiting for the next scheduled visit.
Lifestyle factors are within your control as well. Avoiding alcohol during chemotherapy removes one additional source of liver stress. Maintaining a healthy diet, staying physically active within your energy limits, and keeping your weight as stable as possible can help your liver cope better with the chemical demands of treatment. Be cautious with over-the-counter medications, especially acetaminophen, which is processed by the liver and can compound chemotherapy-related strain at high doses. And resist the urge to add supplements without checking with your oncologist first. “Natural” does not mean safe during chemotherapy, and some herbal products are themselves hepatotoxic or can interfere with drug metabolism in unpredictable ways.